Boston, Mass. – Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapies for sickle cell disease, including one that uses a type of novel genome editing technology. The new therapies...
Latest News
MARLBOROUGH, Mass. – Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma (HCC). The approval expands access to this life-prolonging therapy for a greater number of patients, which,...
Boston, Mass. — Each year, approximately 2,000 people die annually of gallbladder cancer (GBC) in the U.S., with only one in five cases diagnosed at an early stage. With GBC rated as the first biliary tract cancer and the 17th most deadly cancer worldwide, pressing attention for proper management of...
Boston, Mass. — Dennis Jones, PhD, assistant professor of pathology & laboratory medicine at Boston University Chobanian & Avedisian School of Medicine, has been awarded a two-year, $330,000 grant from the Department of Defense for his research, “Enhancing Lymphatic Function with Transplanted Muscle Cells after Bacterial Infection.” Lymphedema is a...
BOSTON, Mass. — David T. Felson, MD, MPH and Tuhina Neogi, MD, PhD professors of medicine at Boston University Chobanian & Avedisian School of Medicine and of epidemiology at the School of Public Health, have been awarded a U19 grant from the NIH’s National Institute on Aging. The five-year, $46...
Boston, Mass. – Identifying genetic variants and the role they play in predisposing people to Alzheimer’s disease can help researchers better understand how to treat the neurodegenerative condition for which there is currently no cure. A new study led by Boston University School of Public Health (BUSPH) and UTHealth Houston...
WALTHAM, Mass. — BostonGene, a leading provider of AI-based molecular and immune profiling solutions provider, today announces a collaboration with Prisma Health aimed at advancing the understanding of rare tumors by characterizing the tumor microenvironment (TME), mutational landscape and host immune profiles of patients treated with immune checkpoint inhibitors. In...
LEXINGTON, Mass. — Agenus Inc., a leader in developing immunological cancer treatments, today announced results from the NEST-1 study, an investigator-sponsored trial (IST) evaluating the combination of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colorectal cancer (CRC), both those with Microsatellite Stable (MSS) CRC and Microsatellite Instability High...
LMU researchers have identified a signaling pathway by which aspirin can inhibit colorectal cancer. Munich, Germany — Colorectal cancer (bowel cancer) is the third most common form of cancer worldwide, with around 1.9 million newly diagnosed cases and 900,000 deaths every year. Therefore, preventive substances represent an urgent clinical need....
GRAND RAPIDS, Mich. – Six-year-old Jacob Geer takes 12 pills every day to control his seizures, is fed by a tube and regularly visits a variety of doctors. He will be lucky to celebrate his 12th birthday. One year ago, Jacob was diagnosed with Batten disease, a genetic disorder of...